IMR Press / JIN / Special Issues / photobiomodulation

From Bench to Bedside: Photobiomodulation for Parkinson's Disease

Submission deadline: 30 June 2023
Special Issue Editor
  • Cecile Moro, PhD
    CEA-Leti /Clinatec, 17 avenue des Martyrs, Grenoble, France
    Interests: photobiomodulation; Parkinson's disease; medical devices; brain computer interfaces; myocardial ischemia; neuroprotection; substantia nigra; low-level light therapy
Special Issue Information

Dear Colleagues,

Photobiomodulation (PBM) therapy is based on exposing cells to non-ionizing low level light radiation with a wavelength generally ranging from 600 to 1400 nm which results in biological consequences after absorption by endogenous chromophores. Over the past few decades, biomedical research relating to photobiomodulation has been constantly increasing, indicating a growing interest in its therapeutic potential.

Both in vitro and in vivo studies have evaluated the effect of PBM in Parkinson’s disease models. A neuroprotective effect of the dopaminergic neurons, a reduction in astrogliosis and a GDNF striatal expression increase have been demonstrated in toxin induced and transgenic animal models.

The translation of these studies to clinical utilization requires adaptations, so that PBM can reach intracerebral regions. Implanted medical devices have been developed to bring light directly into the brain. Less invasive approaches through transcranial illumination have a methodological advantage. Nevertheless, the low probability of reaching the deeper intracerebral regions to the areas of main pathology in the brainstem limits their use. In all cases, PBM seems to be well tolerated, with minimal or no side-effects or toxicity.

The main mechanism of action of PBM involves the stimulation of mitochondria and reduction of oxidative stress. However, the mechanism of action is not yet fully understood and the role of a systemic component remains to be assessed. The effects of PBM treatment are also modulated by the illumination parameters with an obvious hormetic effect.

Considering its ease of use, utilization of PBM at the bedside via an external application has mainly been evaluated. Pilot and exploratory studies with small numbers of patients provide encouraging early observations, but rigorous clinical trials need to be undertaken. As a better understanding of the mechanisms of action ensues, further studies have the potential to optimize the use of PBM at the bedside.

Dr. Cecile Moro

Guest Editor

low level light therapy
Parkinson disease
neurodegenerative disease
hermetic effect
transcranial illumination
intracranial illumination
PBM mechanism
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Back to top